Tags Drugs and Pharmaceuticals

Tag: Drugs and Pharmaceuticals

Pure MHC, LLC, today announced the launch of its Peptide HLA Immunotherapy Data Resource

eNewsChannels NEWS: -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham

eNewsChannels NEWS: -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research.

Zeteo Biomedical Receives US Patent for its Sublingual Delivery Device for Vaccines and Pharma

eNewsChannels NEWS: -- Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its "Oral Delivery Device and Methods" (US Patent 10238577). This latest patent expands the capabilities of Zeteo's ZEO Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual route.

Caisson Biotech and Heparinex Announce Positive Exam Report of European Patent and the Discovery of a New Class of Sugar Polymers

eNewsChannels NEWS: -- Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.

Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug Designation

eNewsChannels NEWS: -- Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation for the Company's lead drug RSC-57, for the treatment of patients with Kabuki Syndrome.

Kalyagen Launches ‘Stem the Tide of Time’ Campaign Featuring NBA Hall of Fame Finalist Marques Johnson

eNewsChannels NEWS: -- Kalyagen is pleased to announce the launch of its "Stem the Tide of Time" social media campaign featuring former UCLA Bruin and Milwaukee Buck All-Star Marques Johnson to promote STEMREGEN;, a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

Kalyagen Announces Clinical Trial Launch to Evaluate STEMREGEN and Stem Cells for Advanced Heart Failure Patients

eNewsChannels NEWS: -- Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure.

Pharmaceutical Strategies Group acquired by EPIC Insurance Brokers and Consultants

eNewsChannels NEWS: -- EPIC Holdings, Inc. (EPIC) announced today that it has agreed to acquire Pharmaceutical Strategies Group (PSG). The move incorporates the expertise and resources of the nation's largest independent pharmacy benefit consulting firm into EPIC's Employee Benefits Consulting practice.

Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID-19 Vaccine Under Fast Track CARES Act

eNewsChannels NEWS: -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.

Avila Herbals Announces Research and Development Agreements with Phoenix Biotechnology

eNewsChannels NEWS: -- Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology.

WHAT'S NEWS